Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Valerie J. Waters, Timothy J. Kidd, Rafael Canton, Miquel B. Ekkelenkamp, Helle Krogh Johansen, John J. Lipuma, Scott C. Bell, J. Stuart Elborn, Patrick A. Flume, Donald R. Vandevanter, Peter Gilligan, Wendy Bullington, Pierre Regis Burgel, Catherine Byrnes, Pavel Drevinek, Alison Holmes, Barbara Kahl, Holly Maples, Stacey Martiniano, Susanna McColleyAndrew Morris, Marianne Muhlebach, Michael Parkins, Felix Ratjen, Jason Roberts, Lisa Saiman, Anand Shah, Alan Smyth, Ranjani Somayaji, Giovanni Taccetti, Michael Tunney, Kevin Winthrop, Edith Zemanick

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.

Original languageEnglish (US)
Pages (from-to)1812-1816
Number of pages5
JournalClinical Infectious Diseases
Volume69
Issue number10
DOIs
StatePublished - Nov 15 2019

Keywords

  • antimicrobial susceptibility
  • cystic fibrosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections'. Together they form a unique fingerprint.

Cite this